is it advisable to take propecia and cials at the same time

by sam007

FINASTERIDE is used to treat benign prostatic hyperplasia (bph) in men. This is a condition that causes you to have an enlarged prostate. This medicine helps to control your symptoms, diminish urinary retention, and reduces your risk of needing surgery. When used in combination with sure other medicines, this drug can slow down the progression of your disease.

What may interact with this medicine? male hormones like testosterone

Generic Name: tadalafil Brand Name: Cialis

A phosphodiesterase inhibitor - It is used to treat erection problems in men

Do not take whether you have any of these conditions: eye or vision problems, including a infrequent inherited eye disease called retinitis pigmentosa heart disease, angina, a history of heart attack, irregular heart beats, or other heart problems high or low blood pressure kidney or liver disease stroke an unusual or allergic reaction to tadalafil, other medicines, foods, dyes, or preservatives

What may interact with this medicine? Do not take this medicine with any of the following medications: nitrates like amyl nitrite, isosorbide dinitrate, isosorbide mononitrate, nitroglycerin

This medicine may also interact with the following medications: sure drugs for high blood pressure certain drugs for the treatment of Hiv infection or Aids certain drugs used for fungal or yeast infections, like fluconazole, itraconazole, ketoconazole, and voriconazole sure drugs used for seizures like carbamazepine, phenytoin, and phenobarbital grapefruit juice macrolide antibiotics like clarithromycin, erythromycin, troleandomycin medicines for prostate problems rifabutin, rifampin or rifapentine

This list may not describe all possible interactions. Give your health care provider a list of all the medicines, herbs, non-prescription drugs, or dietary supplements you use. Also tell them if you smoke, drink drink, or use illegal drugs. Some items may interact with your medicine.

...

Read more...

LegalNewsline | Drug company will pay $3.8M in Massachusetts

by Nick Rees

BOSTON (Legal Newsline) - Massachusetts Attorney General Martha Coakley has reached a settlement with a New Jersey-based pharmaceutical manufacturer over alleged false and inflated price reports.

Actavis Elizabeth LLC agreed to a $3.6 million settlement over its reports to drug industry price reporting services that caused, Coakley claims, the Massachusetts Medicaid Program to pay inflated amounts for ingredient costs on prescriptions for Medicaid recipients.

"The Massachusetts Medicaid Program provides critical health care services to thousands of Massachusetts residents," Coakley said.

"This settlement represents a positive step forward in our efforts to address false price reporting, an issue that continues to afflict the program.

"Our office will continue to work with MassHealth and the federal government to maintain the integrity of the pharmaceutical reimbursement program and ensure that it is fair to all involved parties."

Actavis was sued in 2003 as part of a group of 13 generic drug manufacturers for alleged false inflation of the prices they reported to national pharmaceutical price reporting services.

Those reported prices were used by the commonwealth's Medicaid Program to determine what would be paid to pharmacies for ingredient costs in connection with prescription drugs.

The false and inflated prices, the commonwealth alleged, caused the Medicaid Program to pay inflated amounts for ingredient costs for prescriptions for Medicaid recipients.

The settlement resolves claims against Actavis related to drugs manufactured and sold from 1997-2003, including Clonazapam, Isosorbide Mononitrate and Lorazapam. Actavis did not admit any wrongdoing in agreeing to the settlement and asserted that its price reporting was consistent with all legal standards.

Actavis, which was formerly known as Purepac Pharmaceutical Co., is a subsidiary of Actavis Group hf, an Icelandic firm that manufactures and...

Read more...

Buy Isosorbide Mononitrate Without a Prescription

by Wentony

Use Isosorbide Mononitrate as directed by your doctor. Take Isosorbide Mononitrate with or without a meal. Isosorbide Mononitrate is usually taken twice a day, with seven hours interval between the doses. The first dose should preferably be taken in the morning upon waking up, unless directed otherwise by your doctor. If you need to stop taking Isosorbide Mononitrate or add a new medicine, your doctor will gradually lower your dose. Isosorbide Mononitrate may cause dizziness or lightheadedness. These effects may worsen if Isosorbide Mononitrate is taken with alcohol or certain other medications. Use Isosorbide Mononitrate with caution. Do not drive or perform other possibly unsafe tasks until you know how you react to this drug. If your symptoms do not improve or if they worsen, contact your doctor. Isosorbide Mononitrate should be used only by the patient for whom it has been prescribed. Do not take less or more or take it more often than prescribed by your doctor.

Source: Buy Isosorbide Mononitrate Without a Prescription

Ethex Corp Recalls Several Generic Drugs

lots of dextroamphetamine sulfate tablets, propafenone HCl tablets, isosorbide mononitrate extended release tablets, and morphine sulfate ...

Isosorbide Mononitrate - News


Drug company will pay $3.8M in Massachusetts
Legal News Line - Mar 10, 2010
Drug company will pay $3.8M in Massachusetts The settlement resolves claims against Actavis related to drugs manufactured and sold from 1997-2003, including Clonazapam, Isosorbide Mononitrate and

Lotus Pharmaceuticals Announces New Prescription Drugs
PR Newswire (press release) - Mar 02, 2010
The Company's product pipeline pending final SFDA approval status includes Isosorbide Mononitrate-Sustained Release Tablets for cardiovascular disease,

Attorney General Martha Coakley's Office Reaches $3.6M Settlement with Drug ...
Citybizlist (press release) - Mar 09, 2010
related to the drugs that Actavis manufactured and sold during the years 1997 to 2003, including Clonazapam, Isosorbide Mononitrate and Lorazapam.

Pain Relief Directory

Isosorbide mononitrate - Wikipedia, the free encyclopedia
Isosorbide mononitrate is a drug used principally in the treatment of angina pectoris[1] and acts by dilating the blood vessels so as to reduce the blood pressure. ...

isosorbide mononitrate (Imdur, Ismo, Monoket) Drug ...
Information on the drug isosorbide mononitrate (Imdur, Ismo, Monoket), a nitrate used to treat angina pectoris (heart pain, chest pain). Side effects, drug ...

Ismo (Isosorbide Mononitrate) Drug Information: Uses, Side ...
Learn about the prescription medication Ismo (Isosorbide Mononitrate), drug uses, dosage, side effects, drug interactions, warnings, and patient labeling.

Isosorbide mononitrate: Definition from Answers.com
isosorbide mononitrate n trade name: ISMO; drug class: antianginal, organic nitrate; action: decreases preload/afterload, which is responsible for

Isosorbide Mononitrate Information from Drugs.com
Isosorbide mononitrate is used to prevent angina attacks (chest pain). Includes isosorbide mononitrate side effects, interactions and indications.

Drug company will pay $3.8M in Massachusetts

10.03.10

BOSTON (Legal Newsline) - Massachusetts Attorney General Martha Coakley has reached a settlement with a New Jersey-based pharmaceutical manufacturer over alleged false and inflated price reports.

Actavis Elizabeth LLC agreed to a $3.6 million settlement over its reports to drug industry price reporting services that caused, Coakley claims, the Massachusetts Medicaid Program to pay inflated amounts for ingredient costs on prescriptions for Medicaid recipients.

"The Massachusetts Medicaid Program provides critical health care services to thousands of Massachusetts residents," Coakley said.

"This settlement represents a positive step forward in our efforts to address false price reporting, an issue that continues to afflict the program.

"Our office will continue to work with MassHealth and the federal government to maintain the integrity of the pharmaceutical reimbursement program and ensure that it is fair to all involved parties."

Actavis was sued

Source: Legal News Line

Lotus Pharmaceuticals Announces New Prescription Drugs

02.03.10

Sells drugs directly and indirectly through its national sales channels to hospitals, clinics and drugs stores in 30 provinces of the PRC.

Safe Harbor Statement

This press release contains "forward-looking statements" within the meaning of the "safe-harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intent," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will likely," "should," "could," "would," "may," or words or expressions of similar meaning. Such statements are not guarantees of future performance and could cause the actual results of the Company to differ materially from the results expressed or implied by such statements, including, but not limited to, changes from anticipated levels of sales, future national or regional economic and competitive and regulatory conditions, changes in relationships with customers, access to capital, increased costs, difficulties in developing and marketing new products, marketing existing products, customer acceptance of existing and new products, the time to get new drugs approved by the State Food and Drug Administration and other factors. Additional information regarding risks can be found in the Company's Annual Report on Form 10K and its prior filings with the SEC. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company has no obligation to update the forward-looking information contained in this press release.

Source: PR Newswire (press release)

Attorney General Martha Coakley's Office Reaches $3.6M Settlement with Drug ...

09.03.10

Attorney General Martha Coakley’s Office Reaches $3.6M Settlement with Drug Manufacturer Actavis Elizabeth

BOSTON -- Attorney General Martha Coakley 's Office has reached a $3.6 million settlement agreement with Actavis Elizabeth LLC ("Actavis"), an Elizabeth, New Jersey-based pharmaceutical manufacturer, resolving a Massachusetts False Claims Act case pending in United States District Court in Boston. The lawsuit alleged Actavis reported false and inflated prices to drug industry price reporting services, which caused the Massachusetts Medicaid Program to pay inflated amounts for ingredient costs on prescriptions for Medicaid recipients. The monies recovered will be returned to the Massachusetts Medicaid Program, MassHealth.

"The Massachusetts Medicaid Program provides critical health care services to thousands of Massachusetts residents. This settlement represents a positive step forward in our efforts to address false price reporting, an issue that continues to afflict the program," Attorney General Coakley said. "Our office will continue to work with MassHealth and the federal government to maintain the integrity of the pharmaceutical reimbursement program and ensure that it is fair to all involved parties."

Source: Citybizlist (press release)